A Multicenter Phase 1 Study of γ -secretase inhibitor RO4929097 in Combination with Capecitabine in Refractory Solid Tumors

BACKGROUND: RO4929097 is an oral inhibitor of γ -secretase that results in Notch signaling inhibition. Prior work has demonstrated that Notch signaling inhibition enhances chemotherapy sensitivity of cancer cells. This phase I study was conducted to determine maximum tolerated dose (MTD), toxicities...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Invest New Drugs
Main Authors: LoConte, Noelle K., Razak, Albiruni R. A., Ivy, Percy, Tevaarwerk, Amye, Leverence, Rachael, Kolesar, Jill, Siu, Lillian, Lubner, Sam J., Mulkerin, Daniel L., Schelman, William R., Deming, Dustin A., Holen, Kyle D., Carmichael, Lakeesha, Eickhoff, Jens, Liu, Glenn
Formato: Artigo
Idioma:Inglês
Publicado: 2014
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4297251/
https://ncbi.nlm.nih.gov/pubmed/25318436
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0166-6
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares